【中國質量萬里行11月29日訊】11月24日(ri)，中(zhong)(zhong)藥(yao)編(bian)碼國(guo)家標(biao)準(zhun)驗收會(hui)通(tong)過了康(kang)美(mei)藥(yao)業(ye)(ye)承擔參與的(de)444個中(zhong)(zhong)藥(yao)飲片、146個中(zhong)(zhong)藥(yao)材(cai)和2000多個品(pin)規的(de)認證(zheng)，驗證(zheng)通(tong)過的(de)中(zhong)(zhong)藥(yao)飲片品(pin)種(zhong)基(ji)本全部覆蓋中(zhong)(zhong)醫臨床常用藥(yao)，標(biao)志著康(kang)美(mei)藥(yao)業(ye)(ye)成(cheng)為全國(guo)首家通(tong)過中(zhong)(zhong)藥(yao)編(bian)碼國(guo)家標(biao)準(zhun)驗證(zheng)的(de)企業(ye)(ye)，這也(ye)是康(kang)美(mei)藥(yao)業(ye)(ye)繼11月18日(ri)牽(qian)頭啟動(dong)國(guo)家發改委新興產(chan)業(ye)(ye)重大工程包“三(san)七等20種(zhong)中(zhong)(zhong)藥(yao)飲片標(biao)準(zhun)化(hua)項目”之(zhi)后又一(yi)個國(guo)家中(zhong)(zhong)醫藥(yao)標(biao)準(zhun)化(hua)的(de)正式實施(shi)。

　　此次認證的(de)(de)順利完成(cheng)標(biao)(biao)(biao)志著康(kang)美藥(yao)(yao)業參與(yu)的(de)(de)《中(zhong)藥(yao)(yao)方(fang)劑(ji)編(bian)碼(ma)規(gui)則及編(bian)碼(ma)》、《中(zhong)藥(yao)(yao)編(bian)碼(ma)規(gui)則及編(bian)碼(ma)》和(he)《中(zhong)藥(yao)(yao)在供應鏈管理中(zhong)的(de)(de)編(bian)碼(ma)與(yu)標(biao)(biao)(biao)識》3項(xiang)(xiang)中(zhong)醫(yi)藥(yao)(yao)國(guo)家(jia)標(biao)(biao)(biao)準的(de)(de)落地實(shi)施。長期以(yi)(yi)來，中(zhong)醫(yi)藥(yao)(yao)行(xing)業存在“同方(fang)異名”“異方(fang)同名”“同物(wu)異名”“異物(wu)同名”等(deng)現(xian)象，此次3項(xiang)(xiang)國(guo)家(jia)編(bian)碼(ma)標(biao)(biao)(biao)準的(de)(de)發布實(shi)施，將(jiang)有助于推(tui)動全國(guo)實(shi)現(xian)中(zhong)藥(yao)(yao)方(fang)劑(ji)、中(zhong)藥(yao)(yao)名稱、品種及其規(gui)格“一(yi)名、一(yi)方(fang)、一(yi)物(wu)、一(yi)碼(ma)”，對打擊中(zhong)藥(yao)(yao)材、中(zhong)藥(yao)(yao)飲片以(yi)(yi)假(jia)充(chong)真、以(yi)(yi)劣充(chong)優(you)現(xian)象，凈化中(zhong)藥(yao)(yao)材市場具有積(ji)極意義。康(kang)美藥(yao)(yao)業作為中(zhong)醫(yi)藥(yao)(yao)龍頭(tou)企(qi)業，充(chong)分利用“互聯(lian)網+大健康(kang)”全產業鏈資源(yuan)優(you)勢，參與(yu)了(le)多(duo)個中(zhong)醫(yi)藥(yao)(yao)標(biao)(biao)(biao)準化制(zhi)定，為中(zhong)醫(yi)藥(yao)(yao)標(biao)(biao)(biao)準化創新發展(zhan)積(ji)累了(le)豐富的(de)(de)經驗。

　　在(zai)康(kang)美藥業(ye)中(zhong)(zhong)藥基地二期驗收會現場(chang)，由深(shen)圳(zhen)市(shi)(shi)衛計委中(zhong)(zhong)醫藥標準化辦公室(shi)主任、中(zhong)(zhong)醫藥企業(ye)標準聯盟主席廖利平，市(shi)(shi)人(ren)民醫院(yuan)主任原(yuan)文鵬，藥品檢驗研究院(yuan)主任王淑紅等組成的專家(jia)組分(fen)為資質小組、質量(liang)小組、信息小組分(fen)別開展(zhan)了現場(chang)認(ren)證與標識工作，專家(jia)組對康(kang)美藥業(ye)中(zhong)(zhong)藥編碼認(ren)證與標識的準備工作給予了高度評價與充(chong)分(fen)肯定(ding)。

　　專家(jia)組指出，康(kang)美藥(yao)業(ye)牽頭承(cheng)擔的(de)中(zhong)(zhong)藥(yao)編(bian)碼(ma)(ma)為構建中(zhong)(zhong)藥(yao)質量(liang)溯源體(ti)系，打造貿(mao)易公(gong)(gong)平、公(gong)(gong)正、透明的(de)平臺，提供(gong)基礎(chu)數(shu)據庫、中(zhong)(zhong)藥(yao)處方與中(zhong)(zhong)藥(yao)飲片(pian)編(bian)碼(ma)(ma)相對接，加快中(zhong)(zhong)醫(yi)藥(yao)標準化、規范化、數(shu)字(zi)化、信息化的(de)進(jin)程(cheng)提供(gong)了(le)(le)有力(li)的(de)技術支撐，推動了(le)(le)中(zhong)(zhong)藥(yao)產業(ye)的(de)轉型升級，提高了(le)(le)藥(yao)品(pin)生產企(qi)業(ye)的(de)公(gong)(gong)信力(li)、權威性、影響力(li)，促進(jin)了(le)(le)中(zhong)(zhong)醫(yi)醫(yi)療(liao)服務和中(zhong)(zhong)藥(yao)產業(ye)適(shi)應“互聯網+”及物聯網發(fa)展需求。

　　康美藥(yao)(yao)業質(zhi)量(liang)(liang)總監姜(jiang)濤表示，中(zhong)藥(yao)(yao)編碼的(de)有(you)效落地實施，將為中(zhong)醫(yi)藥(yao)(yao)和(he)各國(guo)傳統醫(yi)藥(yao)(yao)提(ti)供數字化(hua)(hua)編碼依據和(he)技術標(biao)準，推動中(zhong)藥(yao)(yao)邁向數字化(hua)(hua)、標(biao)準化(hua)(hua)、信(xin)息化(hua)(hua)，這與康美藥(yao)(yao)業全(quan)面打(da)造“互聯網+大健康”全(quan)產(chan)業鏈的(de)發展(zhan)方向是(shi)高度(du)一(yi)致的(de)。康美藥(yao)(yao)業高度(du)重視這項工(gong)(gong)作(zuo)(zuo)，在中(zhong)藥(yao)(yao)質(zhi)量(liang)(liang)溯源體系和(he)藥(yao)(yao)品規范化(hua)(hua)生產(chan)上也將繼續付出努(nu)力，切實推動中(zhong)醫(yi)藥(yao)(yao)國(guo)家標(biao)準工(gong)(gong)作(zuo)(zuo)落地實施，持續助(zhu)力中(zhong)醫(yi)藥(yao)(yao)標(biao)準化(hua)(hua)工(gong)(gong)作(zuo)(zuo)的(de)發展(zhan)。

　　據悉，2015年10月(yue)29日(ri)，國(guo)家標準(zhun)委和國(guo)家中(zhong)(zhong)(zhong)醫(yi)(yi)藥(yao)管理局(ju)在京聯合(he)召開新聞發布會(hui)，發布《中(zhong)(zhong)(zhong)藥(yao)方(fang)劑(ji)編碼(ma)規(gui)則及編碼(ma)》、《中(zhong)(zhong)(zhong)藥(yao)編碼(ma)規(gui)則及編碼(ma)》和《中(zhong)(zhong)(zhong)藥(yao)在供應鏈管理中(zhong)(zhong)(zhong)的編碼(ma)與標識》3項中(zhong)(zhong)(zhong)醫(yi)(yi)藥(yao)國(guo)家標準(zhun)。該(gai)系列標準(zhun)由國(guo)家中(zhong)(zhong)(zhong)醫(yi)(yi)藥(yao)管理局(ju)提(ti)出并歸口，深(shen)圳市(shi)衛生計生委牽(qian)頭，深(shen)圳市(shi)中(zhong)(zhong)(zhong)醫(yi)(yi)院(yuan)(yuan)、深(shen)圳市(shi)標準(zhun)技術研究院(yuan)(yuan)、康美藥(yao)業股份有限(xian)公司、羅(luo)湖區中(zhong)(zhong)(zhong)醫(yi)(yi)院(yuan)(yuan)聯合(he)中(zhong)(zhong)(zhong)國(guo)中(zhong)(zhong)(zhong)醫(yi)(yi)科學院(yuan)(yuan)、廣州(zhou)中(zhong)(zhong)(zhong)醫(yi)(yi)藥(yao)大學、江西中(zhong)(zhong)(zhong)醫(yi)(yi)藥(yao)大學、中(zhong)(zhong)(zhong)國(guo)食品藥(yao)品檢定制品研究院(yuan)(yuan)、中(zhong)(zhong)(zhong)國(guo)物(wu)品編碼(ma)中(zhong)(zhong)(zhong)心、中(zhong)(zhong)(zhong)國(guo)中(zhong)(zhong)(zhong)藥(yao)協會(hui)、中(zhong)(zhong)(zhong)國(guo)中(zhong)(zhong)(zhong)藥(yao)公司、中(zhong)(zhong)(zhong)華中(zhong)(zhong)(zhong)醫(yi)(yi)藥(yao)學會(hui)等單(dan)位40多(duo)個(ge)單(dan)位70多(duo)名專家共同承擔。

　　這(zhe)3項(xiang)標(biao)準于(yu)2015年(nian)12月1日起實(shi)施，標(biao)志著全國實(shi)施統(tong)一(yi)的(de)(de)(de)(de)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)方(fang)(fang)(fang)劑(ji)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)供應鏈(lian)編(bian)碼(ma)(ma)(ma)(ma)體系。其中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)，《中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)方(fang)(fang)(fang)劑(ji)編(bian)碼(ma)(ma)(ma)(ma)規則(ze)及編(bian)碼(ma)(ma)(ma)(ma)》規定了中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)方(fang)(fang)(fang)劑(ji)的(de)(de)(de)(de)分類與代碼(ma)(ma)(ma)(ma)結構，并(bing)對1089首(shou)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)方(fang)(fang)(fang)劑(ji)進行(xing)了分類編(bian)碼(ma)(ma)(ma)(ma)，該套編(bian)碼(ma)(ma)(ma)(ma)實(shi)施后，中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)方(fang)(fang)(fang)劑(ji)的(de)(de)(de)(de)臨床用(yong)藥(yao)(yao)(yao)(yao)(yao)、科研(yan)教學、統(tong)計和監督管理，以(yi)及中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)方(fang)(fang)(fang)劑(ji)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)處(chu)方(fang)(fang)(fang)、電子處(chu)方(fang)(fang)(fang)、電子病歷(li)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)醫病歷(li)等工作的(de)(de)(de)(de)信息(xi)處(chu)理、信息(xi)交換(huan)與互(hu)聯互(hu)通，都將有統(tong)一(yi)、穩(wen)定的(de)(de)(de)(de)數字代碼(ma)(ma)(ma)(ma);《中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)編(bian)碼(ma)(ma)(ma)(ma)規則(ze)及編(bian)碼(ma)(ma)(ma)(ma)》適用(yong)于(yu)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)材(cai)、草藥(yao)(yao)(yao)(yao)(yao)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)飲(yin)片(pian)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)配方(fang)(fang)(fang)顆粒、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)超(chao)(chao)(chao)微(wei)飲(yin)片(pian)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)超(chao)(chao)(chao)微(wei)配方(fang)(fang)(fang)顆粒的(de)(de)(de)(de)分類編(bian)碼(ma)(ma)(ma)(ma)，這(zhe)使中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)配方(fang)(fang)(fang)顆粒、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)超(chao)(chao)(chao)微(wei)飲(yin)片(pian)、中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)超(chao)(chao)(chao)微(wei)配方(fang)(fang)(fang)顆粒等中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)新時代產物(wu)與傳(chuan)統(tong)中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)品種有了基于(yu)同一(yi)規則(ze)的(de)(de)(de)(de)編(bian)碼(ma)(ma)(ma)(ma);《中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)在供應鏈(lian)管理中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)的(de)(de)(de)(de)編(bian)碼(ma)(ma)(ma)(ma)與表示》規定了中(zhong)(zhong)(zhong)(zhong)(zhong)(zhong)藥(yao)(yao)(yao)(yao)(yao)產品貿(mao)易項(xiang)目、產地、單位(wei)、等級、生產日期、批次號(hao)、數量等產品標(biao)識內容信息(xi)的(de)(de)(de)(de)編(bian)碼(ma)(ma)(ma)(ma)。